Decoy Therapeutics Inc(DCOY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -47.29 | Insider Own | 4.59% | Shs Outstand | 2.4M | Perf Week | -5.8% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 2.3M | Perf Month | -9.83% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -2.59 | Inst Own | 4.19% | Short Float | 4.37% | Perf Quarter | -70.53% |
| Income | -0.01B | P/S | 10.94 | EPS this Y | - | Inst Trans | 4.14% | Short Ratio | 0.05 | Perf Half Y | -76.66% |
| Sales | 0.00B | P/B | 0.13 | EPS next 5Y | 80.05% | ROA | -278.04% | Short Interest | 0.10M | Perf YTD | -86.45% |
| Book/sh | 8.12 | P/C | 0.3 | EPS past 3/5Y | 81.8% 62.32% | ROE | -827.77% | 52W High | -94.92% ($20.76) | Perf Year | -92.36% |
| Cash/sh | 3.48 | P/FCF | - | Sales past 3/5Y | - | ROIC | -334.41% | 52W Low | 17.22% ($0.90) | Perf 3Y | -99.9% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 91.92% | Gross Margin | 89.24% | Volatility(W/M) | 7.24% 8.12% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | -25.1 | Sales Y/Y TTM | - | Oper. Margin | -2679.3% | ATR (14) | 0.15 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 1.83 | EPS Q/Q | 94.51% | Profit Margin | -6347.85% | RSI (14) | 35.59 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.83 | Sales Q/Q | - | SMA20 | -3.15% ($1.08) | Beta | 0.74 | Target Price | $3 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/08/14 | SMA50 | -41.84% ($1.81) | Rel Volume | 0.02 | Prev Close | $1.09 |
| Employees | 11 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -79.39% ($5.09) | Avg Volume(3M) | 2.13M | Price | $1.05 |
| IPO | 2015/1/29 | Option/Short | No/Yes | Trades | 139 | Volume | 45,226 | Change | -3.21% |
💊 A biotech company that has relaunched under a new name in 2026. It is developing therapeutics for respiratory viruses and gastrointestinal cancers using its peptide-conjugate drug platform.
Over the past 1 year, on the lower side
95% below its 1-year high.
Traded less than usual. That is 2% of its average volume.
DCOY has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +80.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,094. Peers typically go for $885.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 4.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
MEDX Horizon Kinetics Medical ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #565 of 597 in the industry
Based on market cap of $3M.
PPBT#564 Purple Biotech Ltd ADR $3M PER - DCOY#565 Decoy Therapeutics Inc $3M PER - 
EOCN#566 Eocene Ltd $2M PER - 
JUNS#567 Jupiter Neurosciences Inc $2M PER - 
CLDI#568 Calidi Biotherapeutics Inc $2M PER - 
FAQ
What kind of company is DCOY?
DCOY belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of DCOY?
The market cap of DCOY is approximately $3M, ranking 5,744 within its sector.
What is the 52-week high and low for DCOY?
DCOY has recorded a 52-week high of $20.76 and a low of $0.90.
